![]() |
HER2-targeted antibody drug conjugate shows encouraging responses, long-lasting clini
In a new study of trastuzumab deruxtecan, a HER2-targeted antibody drug conjugate, researchers observed encouraging responses and long-lasting clinical benefit in several tumor types.
More... |
| All times are GMT -7. The time now is 02:27 PM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2026, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021